Bayer's Revenue Beat May Come With a Profit Miss, JPMorgan Warns

Bayer investors could be forgiven for assuming that a stronger top line translates into a stronger bottom line. JPMorgan's Richard Vosser is not so sure. According to media reports, the analyst expects the German group's revenue to come in 2% above consensus — while forecasting EBITDA 6% below it. The split matters: it points to a business generating more sales than the market anticipates but converting them into profit less efficiently than hoped. These are projections ahead of publication, not reported figures.

Two Bullish Calls, One Cautious Number

JPMorgan kept Bayer at "Overweight" on Friday and reiterated its EUR 61 price target, so the cautious near-term profit view sits alongside a constructive rating. UBS struck a similar tone on Thursday, confirming a "Buy" recommendation and an unchanged EUR 62 target, according to media reports. Both houses are clearly positive on the equity. Neither recommendation, however, implies that Bayer will beat consensus across every metric — and Vosser's projected gap between sales and EBITDA is precisely why valuation and short-term earnings quality deserve separate scrutiny.

Laboratory Progress on Two Fronts

Away from the numbers, the pharmaceutical pipeline has produced two distinct pieces of news. Roughly two weeks ago, the US Food and Drug Administration accepted Bayer's marketing application for Finerenon in chronic kidney disease without diabetes, an application backed by positive results from the Phase III FIND-CKD trial, per company statements. Acceptance is not approval.

More recently — on Friday — subsidiary Vividion Therapeutics dosed the first patient in a global Phase II study. The trial pairs VVD-214 with Pembrolizumab as a first-line treatment for advanced MSI-H or dMMR colorectal cancer, enrolling approximately 140 patients across sites in around 21 countries. It targets previously untreated patients whose tumors carry the MSI-H or dMMR designation, a narrowly defined population rather than colorectal cancer patients at large.

The two milestones sit at different stages of development: one has cleared a regulatory intake hurdle, the other has just entered clinical testing. Neither an accepted application nor a first patient dosed constitutes proof of efficacy, and no economic gain can be inferred from either.

A Competitor's Warning Lands on Bayer's Share Price

Bayer's stock came under pressure on Thursday for reasons unrelated to its own announcements. Media reports linked the weakness to a disappointing forecast from FMC, which weighed on Bayer shares as well. The trigger originated at another company, which separates the share-price reaction from the Vividion development — a clinical update says nothing about agricultural markets, and a rival's guidance says nothing about the outcome of the colorectal cancer trial.

November 3 Is the Date That Counts

The next scheduled checkpoint is Bayer's quarterly statement for the third quarter of 2026, due on November 3, 2026. That release should show whether the EBITDA shortfall Vosser anticipates actually materializes. Until then, the Vividion study start stands as a concrete research step — not as revenue already booked.